|
Partnering with the NHS
At Bristol-Myers Squibb, we recognise the
significant challenges that the NHS is facing.
Public expectations of what the NHS should
deliver are constantly rising. The public rightly want
fast access to high quality care at a time and place
that is convenient to them.
 However, the global recession will mean that less
money is available to the NHS than has been the
case over the past decade. The challenge for the
NHS, therefore, will be to meet these public
expectations with fewer resources.
We believe that our portfolio of existing and
pipeline medicines can be part of the solution to
these challenges. These new medicines will offer
opportunities for the NHS to provide patients with better
outcomes and better quality of life. Yet we also recognise that
new treatments will present challenges to the NHS.
New medicines often increase the upfront cost of healthcare.
They may also require staff training, new capacity or changes to
patient pathways. At a time when resources are stretched it is
ever more important that the NHS gets the most out of the new
medicines it invests in, in terms of both clinical outcomes and
patient experience.
In recognition of this, our approach at Bristol-Myers Squibb is to
work in partnership with the NHS to make sure that it gets
maximum value from making our medicines available to patients.
We have already begun to build our capabilities to be able to
deliver on this strategy. We have teams in place who can identify
who the right people are to talk to about our products and who
are able to develop new ways of working with these customers
to develop win-win partnerships. These are partnerships that
support the delivery of higher quality services, that can be
accessed by more patients and that incorporate the use of the
most effective medicines.
To ensure that a win-win partnership is struck, our teams are
becoming more flexible when it comes to meeting customer
needs rather than trying to apply a one-size-fits-all solution. In
fact, we are now regularly having conversations with payers about
providing a whole service and not just medicines.
Ultimately, however, what we are trying to do when it comes to
enhancing access is to communicate the value behind our
innovative products not just the actual cost of the product but
the value proposition that supports it.
Partnerships that bring value to the NHS
In order to meet its chosen strategy, every partnership entered into by Bristol-Myers Squibb with the NHS
must be underpinned by four key undertakings:
- Bristol-Myers Squibb endeavours to continually develop medicines to meet true unmet medical
need across a range of disease areas
- We are committed to enhancing clinical excellence through clinical research activities
- We will provide robust evidence on our medicines to support NHS decision makers
- Bristol-Myers Squibb is striving to improve its service delivery so that its medicines reach the right
patients at the right time.
|
